Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Dividends and Buybacks
Dividend criteria checks 0/6
Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd is a dividend paying company with a current yield of 1.71%.
Key information
1.7%
Dividend yield
0%
Buyback Yield
| Total Shareholder Yield | 1.7% |
| Future Dividend Yield | n/a |
| Dividend Growth | 11.6% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | HK$0.0436 |
| Payout ratio | 94% |
Recent dividend and buyback updates
Recent updates
Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's (HKG:1349) Problems Go Beyond Poor Profit
Nov 04
There's Reason For Concern Over Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s (HKG:1349) Massive 51% Price Jump
Oct 14Earnings Troubles May Signal Larger Issues for Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (HKG:1349) Shareholders
May 06What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend
Apr 12We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease
Mar 22Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Mar 07Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?
Feb 20Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?
Feb 07Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?
Jan 25Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?
Jan 12Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?
Dec 28Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly
Dec 15Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?
Dec 03Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Nov 21Stability and Growth of Payments
Fetching dividends data
Stable Dividend: 1349's dividend payments have been volatile in the past 10 years.
Growing Dividend: 1349's dividend payments have fallen over the past 10 years.
Dividend Yield vs Market
| Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (1349) | 1.7% |
| Market Bottom 25% (HK) | 3.2% |
| Market Top 25% (HK) | 8.0% |
| Industry Average (Pharmaceuticals) | 3.7% |
| Analyst forecast (1349) (up to 3 years) | n/a |
Notable Dividend: 1349's dividend (1.71%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (3.17%).
High Dividend: 1349's dividend (1.71%) is low compared to the top 25% of dividend payers in the Hong Kong market (8.04%).
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (93.7%), 1349's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: 1349 is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 16:18 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Hu | Deutsche Bank |
| Feng Qiang Sun | Guotai Junan International Holdings Limited |
| Xiang Jun | Industrial Securities Co. Ltd. |